IL18 and COVID-19: To this end, aberrant activation of inflammasomes might play a role, and it has recently been shown that the serum levels of inflammasome-derived products, namely active caspase-1 (the p20 subunit) and interleukin (IL)-18, correlate with poor clinical outcomes in patients with COVID-19 [4].